全文获取类型
收费全文 | 63438篇 |
免费 | 4293篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 613篇 |
儿科学 | 2551篇 |
妇产科学 | 1674篇 |
基础医学 | 8004篇 |
口腔科学 | 703篇 |
临床医学 | 9403篇 |
内科学 | 10999篇 |
皮肤病学 | 903篇 |
神经病学 | 5933篇 |
特种医学 | 1215篇 |
外科学 | 5825篇 |
综合类 | 680篇 |
一般理论 | 120篇 |
预防医学 | 8717篇 |
眼科学 | 889篇 |
药学 | 4217篇 |
中国医学 | 65篇 |
肿瘤学 | 5344篇 |
出版年
2023年 | 361篇 |
2022年 | 524篇 |
2021年 | 1441篇 |
2020年 | 936篇 |
2019年 | 1408篇 |
2018年 | 1616篇 |
2017年 | 1261篇 |
2016年 | 1336篇 |
2015年 | 1539篇 |
2014年 | 2132篇 |
2013年 | 3217篇 |
2012年 | 4660篇 |
2011年 | 4922篇 |
2010年 | 2721篇 |
2009年 | 2381篇 |
2008年 | 4284篇 |
2007年 | 4427篇 |
2006年 | 4268篇 |
2005年 | 4373篇 |
2004年 | 4173篇 |
2003年 | 3861篇 |
2002年 | 3597篇 |
2001年 | 559篇 |
2000年 | 414篇 |
1999年 | 548篇 |
1998年 | 723篇 |
1997年 | 653篇 |
1996年 | 521篇 |
1995年 | 511篇 |
1994年 | 460篇 |
1993年 | 350篇 |
1992年 | 277篇 |
1991年 | 242篇 |
1990年 | 237篇 |
1989年 | 243篇 |
1988年 | 222篇 |
1987年 | 193篇 |
1986年 | 182篇 |
1985年 | 194篇 |
1984年 | 205篇 |
1983年 | 186篇 |
1982年 | 224篇 |
1981年 | 216篇 |
1980年 | 166篇 |
1979年 | 113篇 |
1978年 | 140篇 |
1977年 | 70篇 |
1976年 | 80篇 |
1975年 | 61篇 |
1974年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
22.
23.
24.
25.
26.
27.
Susan C. Fox Jane A. May Natalia Dovlatova Jackie R. Glenn Andrew Johnson Ann E. White 《Platelets》2019,30(3):290-295
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel. The comparators were light transmission aggregometry (LTA), VerifyNow and Multiplate aggregometry (for determining the effects of aspirin) and LTA, VerifyNow and Multiplate together with the BioCytex VASP phosphorylation assay (for the P2Y12 antagonists). The P-selectin Aspirin Test revealed substantial inhibition of platelet function in all but three of 96 patients receiving aspirin with clopidogrel and in none of 51 patients receiving aspirin and prasugrel. The results were very similar to those obtained using LTA. There was only one patient with high residual platelet aggregation and low P-selectin expression. The same patients identified as “non-responders” to aspirin also presented with the highest residual platelet activity as measured using the VerifyNow system, although not quite as well separated from the other values. With the Multiplate test only one of these patients clearly stood out from the others. The results obtained using the P-selectin P2Y12 Test in 102 patients taking aspirin and clopidogrel were similar to the more traditional approaches in that a wide scatter of results was obtained. Generally, high values seen with the P-selectin P2Y12 Test were also high with the LTA, VerifyNow, Multiplate, and BioCytex VASP P2Y12 Tests. Similarly, low residual platelet function using the P2Y12 test was seen irrespective of the testing procedure used. However, there were differences in some patients. Prasugrel was always more effective than clopidogrel in inhibiting platelet function with none of 56 patients (P-selectin and VerifyNow), only 2 of 56 patients (Multiplate) and only 3 of 56 patients (Biocytex VASP) demonstrating high on-treatment residual platelet reactivity (HRPR) defined using previously published cut-off values. The exception was LTA where there were 11 of 56 patients with HRPR. It remains to be seen which experimental approach provides the most useful information regarding outcomes after adjusting therapies in treated patients. 相似文献
28.
29.
30.
Joseph M. Northey Kate L. Pumpa Clare Quinlan Ashley Ikin Kellie Toohey Disa J. Smee Ben Rattray 《Journal of Science and Medicine in Sport》2019,22(5):580-585